Glioblastoma, the most common and aggressive primary brain cancer in adults, has yielded thousands of previously hidden genetic clues in a study that could reshape the search for future immunotherapies. Researchers from the Clinical Neuroscience Consortium at The University of Hong Kong and the Hong Kong Genome Institute have created the most detailed map yet of the molecular “isoform” diversity found inside these tumours. Using long-read single-cell sequencing, they identified genetic transcripts that conventional methods could not fully see, including tumour-specific molecules that may eventually help immune cells distinguish cancer from healthy tissue.
The findings, published in Nature Communications, address one of the central problems in glioblastoma research: no two tumour cells are necessarily alike. Even within a single patient, cancer cells can differ in their growth patterns, biological behaviour and response to treatment. This cellular variation is one reason glioblastoma frequently returns after surgery, radiotherapy and chemotherapy. By examining the genetic activity of individual cells rather than treating a tumour as a uniform mass, the researchers were able to study its complexity at a far higher resolution.
The key focus of the investigation was isoforms, alternative versions of the molecular messages produced from the same gene. When a gene is activated, its DNA sequence is copied into RNA, which can then be processed in different ways. These alternative RNA molecules may produce proteins with distinct structures and functions. In cancer, changes in isoform production can influence how cells divide, invade surrounding tissue, resist treatment or interact with the immune system. Some isoforms may also create abnormal protein fragments that mark cancer cells for immune attack.
Until recently, scientists have struggled to investigate these molecules in individual tumour cells because standard single-cell sequencing technologies generally read only short fragments of RNA. Those fragments can reveal which genes are active, but they often cannot show the complete structure of a transcript. As a result, different isoforms may be difficult to distinguish, and rare tumour-specific versions can remain invisible. Long-read sequencing overcomes this limitation by reading much longer RNA molecules, allowing researchers to identify full-length transcripts and connect their molecular components accurately.
In this study, the team analysed data from more than 210,000 individual cells collected from 27 patients with glioblastoma. The analysis included malignant cells as well as immune cells and stromal cells in the tumour microenvironment—the network of non-cancerous cells and tissues that surrounds and supports a tumour. This broad approach enabled the researchers to examine not only the genetic diversity of the cancer itself, but also the molecular relationships between tumour cells and their local biological environment.
The resulting map contained thousands of previously unannotated isoforms, meaning genetic transcripts that had not been recorded in existing reference databases. Many of these newly identified isoforms appeared exclusively in tumour cells and were absent from healthy tissues examined in the analysis. Their restricted distribution is particularly important for drug development: a target found only in cancer cells could, in principle, be attacked without causing the widespread damage associated with targets shared by healthy organs.
The researchers then assessed whether some of the tumour-specific isoforms might generate neoantigens—abnormal protein fragments that can be displayed on the surface of cells by molecules known as major histocompatibility complex class I, or MHC class I. These molecules act like biological presentation platforms. They bind fragments derived from proteins inside a cell and display them to immune cells, including cytotoxic T cells. If the displayed fragment appears abnormal, T cells may recognise the cell as dangerous and destroy it.
A subset of the newly discovered isoforms was predicted to produce peptides capable of binding strongly to MHC class I molecules. This does not yet prove that the peptides trigger an effective immune response in patients, but it identifies candidates for further laboratory and clinical testing. If validated, such molecules could expand the supply of neoantigens available for personalised cancer vaccines, in which a vaccine is designed around the unique molecular features of an individual patient’s tumour. They could also support the development of engineered T-cell therapies or other precision immunotherapy strategies.
The implications are significant, but the discovery is not an immediate change to glioblastoma treatment. The predicted neoantigens must first be confirmed experimentally, including tests showing that they are naturally produced by tumour cells, presented on MHC molecules and recognised by human immune cells. Researchers will also need to determine how consistently these isoforms occur among patients and whether cancer cells can lose them under immune pressure. Nevertheless, the study provides a new route into a previously inaccessible layer of tumour biology, potentially revealing targets missed by gene-level and short-read analyses.
The project also demonstrates the value of combining clinical expertise, brain tumour surgery, oncology and population-scale genomics. By linking long-read sequencing with single-cell analysis, the team established and validated an analytical framework that could be applied to other cancers and clinical datasets. The researchers say the work strengthens Hong Kong’s role in translational genomics and precision medicine. For glioblastoma, a disease that has resisted many conventional therapeutic approaches, the newly exposed world of tumour-specific isoforms may offer one of the most promising sources of future targets for personalised vaccines and immune-based treatments.
Subject of Research: Glioblastoma and tumour-specific isoform diversity
Article Title: Mapping glioblastoma’s isoform diversity using long-read single-cell analysis
News Publication Date: 23 April 2026
Web References: https://www.nature.com/articles/s41467-026-72258-2
References: Nature Communications, DOI: 10.1038/s41467-026-72258-2
Image Credits: The University of Hong Kong
Keywords: glioblastoma, brain cancer, long-read sequencing, single-cell analysis, isoforms, neoantigens, personalised cancer vaccines, immunotherapy, precision medicine, tumour microenvironment
Tags: advances in tumor profiling techniquescancer cell variability and response to therapygenetic mapping of glioblastomagenome mapping in brain tumorsGlioblastoma genetic researchinnovative glioblastoma treatment strategieslong-read single-cell sequencing in brain cancermolecular diversity in glioblastomamolecular transcript analysis in cancerpersonalized immunotherapy targetstumor heterogeneity and treatment resistancetumor-specific molecular isoforms
